Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31462139 | 0.84 | CHRNB2 (0.37) | ALDH1A1HSD17B10CHRM1 | |
| SCHEMBL16599080 | 0.79 | CYP3A4 (0.39) | ALDH1A1LMNACYP3A4HSD17B10CYP2C19 | |
| SCHEMBL29531381 | 0.79 | SMN1; SMN2 (0.39) | ALDH1A1HSD17B10GAACA12CA1 | |
| SCHEMBL29531261 | 0.79 | SMN1; SMN2 (0.39) | ALDH1A1HSD17B10GAACA12CA1 | |
| SCHEMBL7136164 | 0.79 | SMN1; SMN2 (0.39) | ALDH1A1HSD17B10GAACA12CA1 | |
| SCHEMBL11695403 | 0.78 | CHRM1 (0.52) | ALDH1A1LMNACYP3A4CYP2C19GAA | |
| SCHEMBL3910323 | 0.76 | RAB9A (0.39) | ALDH1A1LMNAHSD17B10GAAALOX15 | |
| SCHEMBL31352637 | 0.75 | ALDH1A1 (0.48) | ALDH1A1LMNACYP3A4HSD17B10CYP2C19 | |
| SCHEMBL280605 | 0.75 | — | — | |
| SCHEMBL118486 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-9504747-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2016-11-29 | — | — | US | disclosed |
| US-9504747-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2016-11-29 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20140303232-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20140303232-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-4012445-A | Beta-amino carbonyl catalysts for polyurethane preparation | UNION CARBIDE CORPORATION (US) | 1977-03-15 | — | — | US | disclosed |
| US-4011223-A | POLYMERIZATION CATALYSTS, POLYURETHANES | UNION CARBIDE CORPORATION (US) | 1977-03-08 | — | — | US | disclosed |
| US-3954749-A | MORPHOLINE DERIVATIVES OF AMIDES | UNION CARBIDE CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | ALDH1A1 2488/4885LMNA 679/4885CYP3A4 2978/4885 |
| US-20140303232-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | ALDH1A1 2488/4885LMNA 679/4885CYP3A4 2978/4885 |
| US-20170196979-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | ALDH1A1 2488/4885LMNA 679/4885CYP3A4 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.